RLIP76 in Human Serum in Adults With Rheumatologic Diseases

This study has been withdrawn prior to enrollment.
(Study withdrawn due to lack of staffing resources and subject interest)
Sponsor:
Information provided by:
University of North Texas Health Science Center
ClinicalTrials.gov Identifier:
NCT00861159
First received: September 29, 2008
Last updated: January 11, 2011
Last verified: January 2011

September 29, 2008
January 11, 2011
September 2011
September 2011   (final data collection date for primary outcome measure)
The focus of the present study is limited to establishing validated protocols for detection of anti-RLIP76 antibodies in human sera. [ Time Frame: three years ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00861159 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
RLIP76 in Human Serum in Adults With Rheumatologic Diseases
Measurement Of RLIP76 Auto Antibodies in Human Serum In Adults With Rheumatologic Diseases.

It is the investigators aim to determine the feasibility of directly detecting anti-RLIP76 auto-antibodies in human serum using prepared RLIP76 antigen peptides in persons with rheumatologic disease and persons without rheumatologic diesease ("healthy subjects").

This is an exploratory study conducted to see the feasibility of measuring the anti-RLIP76 antibody and to standardize the methods for its measurement. We will perform these studies on blood samples obtained from human subjects after informed concent for blood draw for research purposes is obtained by the Clinical Research Co-ordinator (CRC).

Observational
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample

The experimental populations subject to study will be 100 outpatients in the rheumatology clinic otherwise undergoing routinely scheduled phlebotomy for standard clinical care purposes.

Carotid Atherosclerosis
Not Provided
1

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
100
September 2011
September 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Adult (age 18+), non-pregnant subjects with previously diagnosed rheumatologic disease will be candidates for the study.

Exclusion Criteria:

  • Children, pregnant women, prisoner, persons with any medical condition that precludes phlebotomy, and patients unwilling or unable to provide consent.
Both
18 Years and older
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00861159
2008-31
Yes
Measurement of RLIP76 Auto Antibodies in Human Serum in Adults with Rheumatologic Disease., University of North Texas Health Science Center
University of North Texas Health Science Center
Not Provided
Principal Investigator: Sanjay Awasthi, MD University of North Texas Health Science Center
University of North Texas Health Science Center
January 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP